Research Article
Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors
Table 1
Association between EGFR and clinicopathologic characteristics in patients with head and neck malignant tumors.
| | Variables | Total () | High EGFR () | Low EGFR () | cOR (95% CI) | value |
| | Age | | | | | | | ≤40 | 33 (33.6) | 15 (50.0) | 18 (26.5) | 1 | | | >40 | 65 (66.3) | 15 (50.0) | 50 (73.5) | 2.78 (1.13-6.80) | 0.025 | | Sex | | | | | | | Male | 62 (63.0) | 22 (73.3) | 40 (58.8) | 1 | | | Female | 36 (37.0) | 8 (26.7) | 28 (41.2) | 1.93 (0.75-4.94) | 0.173 | | Grade | | | | | | | Well | 36 (36.7) | 16 (53.3) | 20 (29.4) | 1 | | | Moderate | 46 (46.9) | 14 (46.7) | 32 (47.1) | 1.83 (0.74-4.54) | 0.193 | | Poor | 16 (16.3) | 0 (0.0) | 16 (23.5) | 26.56 (1.48-476.61) | 0.026 | | Tumor site | | | | | | | Oral cavity | 36 (36.7) | 14 (46.7) | 22 (32.4) | 1 | | | Nasal cavity | 28 (28.6) | 8 (26.7) | 20 (29.4) | 1.59 (0.55-4.58) | 0.390 | | Larynx | 7 (7.1) | 2 (6.7) | 5 (7.4) | 1.59 (0.27-9.53) | 0.607 | | Mandible | 14 (14.2) | 3 (10.0) | 11 (16.2) | 2.33 (0.55-9.87) | 0.249 | | Nasopharynx | 11 (11.2) | 3 (10.0) | 8 (11.8) | 1.70 (0.38-7.50) | 0.486 | | Salivary gland | 1 (1.0) | 0 (0.0) | 1 (1.47) | 1.93 (0.07-50.76) | 0.693 | | Eye | 1 (1.0) | — | 1 (1.47) | NA | NA | | Tumor stage | | | | | | | I | 25 (25.5) | 11 (36.7) | 14 (20.6) | 1 | | | II | 22 (22.4) | 9 (30.0) | 13 (19.1) | 1.13 (0.36-3.62) | 0.831 | | III | 14 (14.3) | 2 (6.7) | 12 (17.6) | 4.71 (0.87-25.61) | 0.073 | | IV | 37 (37.8) | 8 (26.7) | 29 (42.6) | 2.85 (0.94-8.66) | 0.065 |
|
|
